Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-07 11:52 am Purchase |
2025-03-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
The Vanguard Group | 9,311,600 10.000% |
222,209 (+2.44%) |
Filing History |
| 2025-02-10 10:25 am Purchase |
2024-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
WELLINGTON MANAGEMENT CO LLP | 6,950,567 7.500% |
2,490,876 (+55.85%) |
Filing History |
| 2025-02-07 10:23 am Purchase |
2025-01-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
FMR CORP | 9,631,638 10.400% |
727,552 (+8.17%) |
Filing History |
| 2025-02-07 10:06 am Purchase |
2024-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
FMR CORP | 8,904,086 9.600% |
4,860,221 (+120.19%) |
Filing History |
| 2025-01-30 9:33 pm Purchase |
2024-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
The Vanguard Group | 9,089,391 9.800% |
2,801,736 (+44.56%) |
Filing History |
| 2024-11-14 7:55 pm Sale |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
Point72 Asset Management, L.P. | 2,300,643 2.900% |
-1,116,257 (-32.67%) |
Filing History |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
EcoR1 Capital LLC | 4,288,120 4.800% |
132,745 (+3.19%) |
Filing History |
| 2024-11-14 1:22 pm Purchase |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
PRICE T ROWE ASSOCIATES INC | 4,944,757 6.200% |
4,944,757 (New Position) |
Filing History |
| 2024-11-12 2:26 pm Unchanged |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
The Vanguard Group | 6,287,655 7.850% |
0 (Unchanged) |
Filing History |
| 2024-11-08 10:52 am Purchase |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
WELLINGTON MANAGEMENT CO LLP | 4,459,691 5.570% |
1,214,586 (+37.43%) |
Filing History |
| 2024-11-04 11:20 am Purchase |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
The Vanguard Group | 6,287,655 7.850% |
2,785,203 (+79.52%) |
Filing History |
| 2024-10-17 12:47 pm Sale |
2024-09-30 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
STATE STREET CORP STT |
2,838,484 3.600% |
-725,252 (-20.35%) |
Filing History |
| 2024-03-11 3:34 pm Purchase |
2024-02-28 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
EcoR1 Capital LLC | 4,155,375 5.300% |
4,155,375 (New Position) |
Filing History |
| 2024-03-01 8:05 pm Sale |
2023-05-24 | 13D | Crinetics Pharmaceuticals, Inc. CRNX |
PERCEPTIVE ADVISORS LLC | 1,488,703 1.900% |
-3,844,829 (-72.09%) |
Filing History |
| 2024-02-14 6:36 pm Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
ORBIMED ADVISORS LLC | 1,667,360 2.500% |
-1,529,516 (-47.84%) |
Filing History |
| 2024-02-14 4:14 pm Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
Point72 Asset Management, L.P. | 3,416,900 5.100% |
-311,052 (-8.34%) |
Filing History |
| 2024-02-14 4:06 pm Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BRAIDWELL LP | 0 0.000% |
-3,469,674 (Position Closed) |
Filing History |
| 2024-02-14 10:11 am Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-2,736,613 (Position Closed) |
Filing History |
| 2024-02-14 07:54 am Sale |
2023-12-31 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
DRIEHAUS CAPITAL MANAGEMENT INC | 5,039,477 7.540% |
-585,267 (-10.41%) |
Filing History |
| 2024-02-13 5:02 pm Purchase |
2023-12-29 | 13G | Crinetics Pharmaceuticals, Inc. CRNX |
The Vanguard Group | 3,502,452 5.240% |
3,502,452 (New Position) |
Filing History |